GET DAILY SIGNALSSenseonics (SENS) Analysts See $13 Target, Pointing to +37% Upside
Key Takeaways
- The $13 consensus target represents the average of six analyst price targets for Senseonics Holdings, Inc. (SENS), a company focused on implantable continuous glucose monitoring systems.
- Trading near $9.51 recently, the stock would need roughly a 37% advance to hit that level.
- Targets range from $9 to $18, showing meaningful differences in how analysts view the path to sustained profitability.
- Positive drivers include fast Eversense 365 uptake, about 120% year-over-year revenue growth, and an improved 2026 outlook.
- Key risks center on expanding net losses, ongoing cash burn, potential dilution, and competition from much larger diabetes device makers.
- Additional details appear on the Major News, Today's Price Move, Forecast, and Earnings pages.
- Trending AI Robots can provide further perspective on shifting market dynamics.
Analyst Targets and the Consensus Picture
Senseonics Holdings, Inc. (SENS) develops implantable CGM technology, with its Eversense platform offering up to a full year of monitoring through a sensor and rechargeable transmitter. I reviewed six recent analyst targets to arrive at the $13 average.
The spread is notable. Stifel Nicolaus set the lowest at $9 (Hold, up from $8 in early October 2026), while Mizuho Securities placed the highest at $18 (Outperform, down from $20 in July 2026). Other targets include Barclays at $10 (Hold), Lake Street at $12 (Buy), H.C. Wainwright at $14 (Buy), and TD Cowen at $15 (Buy). The simple average comes to $13.00.
Views differ on execution, with optimists highlighting Eversense 365 momentum and margin gains, while others focus on dilution and the shift to direct commercialization.
Where the Stock Stands Today and the Road to $13
Recent trading near $9.51 implies a market cap around $315 million. Closing the gap to $13 would mean about a 37% increase, a meaningful move even for a volatile small-cap name. The 52-week range runs from roughly $4.79 to $10.64, so the target sits above recent highs but within modeled levels.
Continued revenue growth remains central. Second-quarter 2026 revenue climbed about 120% year over year to $14.5 million, led by over 150% U.S. expansion tied to Eversense 365. Management lifted full-year 2026 guidance to $62 million–$66 million and raised gross-margin expectations to 58%–61%. Converting that growth into better cash flow will matter most for any re-rating.
Factors That Could Help Reach the Target
- Robust Eversense 365 adoption, with around 90% of new patients switching from other CGMs and active prescribers rising about 130% year over year.
- Gross margin expansion to roughly 59% in Q2 2026 from 47% the prior year.
- Growth in the direct-to-consumer channel and the Eon Care network, which handles about 40% of U.S. insertions.
- The upcoming Gemini sensor, with an FDA 510(k) submission planned for the first quarter of 2027.
- Physician support and the recurring revenue model from annual sensor replacements.
Obstacles That Could Keep the Target Out of Reach
- Widening losses, with Q2 2026 net loss at $36.7 million ($0.63 per share) versus $14.5 million a year earlier.
- Significant cash use, guided at $110 million–$120 million for 2026 against the revenue range above.
- Dilution risk after the $80 million offering completed in May 2026.
- Competition from much larger players such as DexCom (DXCM), Abbott (ABT), and Medtronic (MDT).
- Higher operating costs from the move to direct commercialization.
Technical Levels Worth Watching
The 52-week high near $10.64 represents important resistance that would likely need to be cleared for a push toward $13. The $10 mark carries psychological weight, with the 50-day moving average around $9.18 just below recent prices. Longer-term support sits near the 200-day average of $7.22, while the 52-week low of $4.79 remains the key downside reference. A decisive break above the prior high would strengthen the bullish structure.
Key Items to Monitor Going Forward
Analyst targets generally look out about 12 months. Investors should track third-quarter 2026 results and any guidance updates, the Gemini submission in early 2027, progress on the Freedom sensor study, margin trends, cash levels, and any further financing or rating changes after earnings.
Checking Signals with AI Tools
I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how momentum aligns with the fundamental picture.
Putting AI Daily Buy/Sell Signals to Work
In my own research process, Tickeron’s AI Daily Buy/Sell Signals help surface timely shifts across thousands of stocks and ETFs. The tool generates Buy, Sell, or Hold signals by combining market conditions, technical factors, and AI analysis, which can complement the fundamental review of names like SENS. It offers a practical way to monitor momentum and spot potential changes without replacing deeper analysis.
Final Assessment
Reaching the $13 average target for Senseonics Holdings (SENS) will depend on maintaining triple-digit revenue growth while narrowing losses without major additional dilution. That consensus, drawn from targets between $9 and $18, suggests roughly 37% upside from recent prices. Strong Eversense 365 demand and margin progress support the upside case, while losses, cash needs, and competition remain the main hurdles. With analysts divided across Hold and Buy ratings, watching earnings, the Gemini timeline, and cash position will be essential. No average target guarantees future results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
SENS in downward trend: price dove below 50-day moving average on November 02, 2026
SENS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend. In 26 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where SENS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The 10-day moving average for SENS crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SENS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SENS's RSI Indicator exited the oversold zone, 40 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SENS as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for SENS just turned positive on October 28, 2026. Looking at past instances where SENS's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +17.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where SENS advanced for three days, in 198 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SENS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.029) is normal, around the industry mean (4.142). P/E Ratio (-3.835) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.058) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative glucose monitoring products
Industry MedicalNursingServices
Advertisement